Vyera Pharmaceuticals – formerly known as Turing Pharmaceuticals – does not have to pay Impax Laboratories $43 million in a dispute stemming from Turing founder Martin Shkreli’s decision to boost by 5,000 percent the price of a drug Turing bought from Impax, a U.S. judge ruled.
The U.S. government is investing more than $170 million to help two new vaccines against Ebola and two Ebola drugs complete the steps needed for FDA approval.
Stopping low-dose aspirin therapy without good reason raises the likelihood of heart attack or stroke by nearly 40 percent, a large Swedish study suggests.
The U.S. Food and Drug Administration approved Novo Nordisk’s fast-acting insulin to treat diabetes.
Shares of Zogenix Inc. more than doubled following the company’s announcement that its investigational Dravet syndrome drug met its primary endpoints in cutting seizure rates in juvenile patients.
Almirall SA announced it plans to halt all research into P3058 (onychomycosis) and P3073 (nail psoriasis) in the U.S. However, clinical trials planned in Europe will continue as scheduled.
Following a review of Phase II efficacy data and a scan of the “evolving marketplace,” Merck & Co. announced that the company was terminating two hepatitis C programs.
The U.S. FDA granted priority review for Roche’s Perjeta in combination with Herceptin and chemotherapy for treating HER2-positive early breast cancer after surgery.
The U.S. Food and Drug Administration approved an Eli Lilly and Co. drug to treat advanced breast cancer that has progressed following prior treatment.
Four U.S. senators have asked the Senate Judiciary Committee to launch an investigation into a deal drugmaker Allergan struck with a Native American tribe to protect some of its patents from generic challenge, according to a letter seen by Reuters.